Evidence map›Paper›PMID 30742063›Full record

ReviewLaboratory investigation; a journal of technical methods and pathology2019

Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy.

Yevgen Chornenkyy, David W Fardo, Peter T Nelson

Open access · bronzeAbstract readReview
In one paragraph

Review in Laboratory investigation; a journal of technical methods and pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 87 citations in OpenAlex.

  1. Article
  2. Article
  3. Atypical features including acquired oculomotor apraxia inJournal of neuromuscular diseases · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Alzheimer mimicry: LATE and PART.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. New criteria to predict LATE-NC in the clinical setting: Probable/Possible LATE and LANS.Journal of neuropathology and experimental neurology · 2025
    Review
  16. Review
  17. Article
  18. A pathologic study of Perivascular pTDP-43 Lin bodies in LATE-NC.Acta neuropathologica communications · 2024
    Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yevgen ChornenkyyUniversity of Kentucky College of Medicine, Lexington, KY, USA.
David W FardoSanders-Brown Center on Aging, Department of Pathology, University of Kentucky, Lexington, KY, USA.
Peter T NelsonUniversity of Kentucky College of Medicine, Lexington, KY, USA. pnels2@email.uky.edu.
University of Kentucky · US

Funding

University of Kentucky Alzheimer's Disease Core Center - Biomarker CoreP30AG028383 · NIA · UNIVERSITY OF KENTUCKY · PI GOLD, BRIAN TIMOTHY, VAN ELDIK, LINDA J · 2006 to 2020
$23.3M
Safety and modulation of ABCC9 pathways by nicorandil for the treatment of hippocampal sclerosis of aging (SMArT–HS)R01AG061111 · NIA · UNIVERSITY OF KENTUCKY · PI JICHA, GREGORY A, NELSON, PETER T. · 2019 to 2025
$3.6M
Novel pathogenetic mechanism for hippocampal sclerosis, a common Alzheimers mimicR01AG057187 · NIA · UNIVERSITY OF KENTUCKY · PI NELSON, PETER T. · 2017 to 2021
$2.2M
CELLULAR CHANGES ALTERING SYNAPTIC CONNECTIVITY IN PRECLINICAL ADR01AG042475 · NIA · UNIVERSITY OF KENTUCKY · PI NELSON, PETER T. · 2013 to 2017
$1.5M
Genomic Architecture of a Key Alzheimer's Disease Mimic: CARTSR56AG057191 · NIA · UNIVERSITY OF KENTUCKY · PI FARDO, DAVID WILLIAM · 2019 to 2020
$1.1M
Impact on Reproductive Aging on Neural-Immune ResponsesR01AG028303 · NIA · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI SOHRABJI, FARIDA · 2006 to 2009
$684k
Testing a therapeutic strategy for hippocampal sclerosis of aging, a key AD mimicR21AG050146 · NIA · UNIVERSITY OF KENTUCKY · PI NELSON, PETER T. · 2016 to 2017
$414k
NIA NIH HHS P30 AG028383NIA NIH HHS R01 AG028303NIA NIH HHS R01 AG042475NIA NIH HHS R01 AG057187NIA NIH HHS R01 AG061111NIA NIH HHS R21 AG050146NIA NIH HHS R56 AG057191
6 · The paper itself

Abstract

We review the literature on Tau and TDP-43 proteinopathies in aged human brains and the relevant underlying pathogenetic cascades. Complex interacting pathways are implicated in Alzheimer's disease and related dementias (ADRD), wherein multiple proteins tend to misfold in a manner that is "reactive," but, subsequently, each proteinopathy may contribute strongly to the clinical symptoms. Tau proteinopathy exists in brains of individuals across a broad spectrum of primary underlying conditions-e.g., developmental, traumatic, and inflammatory/infectious diseases. TDP-43 proteinopathy is also expressed in a wide range of clinical disorders.  Although TDP-43 proteinopathy was first described in the central nervous system of patients with amyotrophic lateral sclerosis (ALS) and in subtypes of frontotemporal dementia (FTD/FTLD), TDP-43 proteinopathy is also present in chronic traumatic encephalopathy, cognitively impaired persons in advanced age with hippocampal sclerosis, Huntington's disease, and other diseases. We list known Tau and TDP-43 proteinopathies.  There is also evidence of cellular co-localization between Tau and TDP-43 misfolded proteins, suggesting common pathways or protein interactions facilitating misfolding in one protein by the other. Multiple pleiotropic gene variants can alter risk for Tau or TDP-43 pathologies, and certain gene variants (e.g., APOE ε4, Huntingtin triplet repeats) are associated with increases of both Tau and TDP-43 proteinopathies. Studies of genetic risk factors have provided insights into multiple nodes of the pathologic cascades involved in Tau and TDP-43 proteinopathies. Variants from a specific gene can be either a low-penetrant risk factor for a group of diseases, or alternatively, a different variant of the same gene may be a disease-driving allele that is associated with a relatively aggressive and early-onset version of a clinically and pathologically specific disease type. Overall, a complex but enlightening paradigm has emerged, wherein both Tau and TDP-43 proteinopathies are linked to numerous overlapping upstream influences, and both are associated with multiple downstream pathologically- and clinically-defined deleterious effects.

Indexed as

Genetic PleiotropyAnimalsHumansTauopathiesTDP-43 Proteinopathies

Identifiers

PMID30742063
PMCPMC6609463
OpenAlexW2912060415

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.